| Not Yet Recruiting | A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors Solid Tumor Cancer | Phase 1 | 2025-04-24 |
| Completed | A Study of [14C]GB491 in Male Healthy Subjects Breast Cancer, Nonsmall Cell Lung Cancer | Phase 1 | 2022-09-14 |
| Unknown | A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor NSCLC, Other Solid Tumors | Phase 1 / Phase 2 | 2022-05-17 |
| Recruiting | A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Breast Cancer | Phase 3 | 2022-01-14 |
| Completed | GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer Locally Advanced or Metastatic Breast Cancer | Phase 3 | 2021-09-10 |
| Unknown | A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. B Cell NHL, CLL | Phase 1 / Phase 2 | 2021-08-31 |
| Unknown | A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer Advanced Breast Cancer | Phase 1 | 2021-06-02 |
| Completed | Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ® Breast Cancer | Phase 1 | 2019-11-13 |
| Unknown | A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis Pati Rheumatoid Arthritis | Phase 1 | 2019-08-15 |
| Unknown | Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib Metastatic Non-small Cell Lung Cancer | Phase 1 | 2019-07-23 |
| Unknown | A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive Cervical Cancer | Phase 2 | 2019-05-23 |
| Unknown | Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer Metastatic Colorectal Cancer | Phase 1 | 2019-04-04 |
| Unknown | Phase Ⅰ Clinical Study Protocol of GB223 Monoclonal Antibody Injection Bone Tumor | Phase 1 | 2018-11-16 |
| Unknown | Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles. Brain Tumor | Phase 1 | 2018-10-16 |
| Unknown | Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226) B-cell Non-Hodgkin's Lymphoma | Phase 2 | 2018-10-15 |
| Unknown | Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226) Alveolar Soft Part Sarcoma | Phase 2 | 2018-09-06 |
| Unknown | Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) Peripheral T Cell Lymphoma | Phase 2 | 2018-07-02 |
| Unknown | Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects Rheumatoid Arthritis | Phase 1 | 2017-11-06 |
| Unknown | Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma Advanced Solid Tumor, Recurrent Solid Tumor, Lymphoma | Phase 1 | 2017-10-19 |
| Unknown | Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for In Rheumatoid Arthritis | Phase 3 | 2017-10-13 |
| Unknown | Clinical Trial in Chinese Healthy Volunteers of GB222 Non-small Cell Lung Cancer | Phase 1 | 2017-04-24 |
| Unknown | Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection HER-2-positive Advanced Breast Cancer | Phase 3 | 2016-11-24 |
| Unknown | Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection HER2-positive Breast Cancer | Phase 1 / Phase 2 | 2014-03-28 |
| Completed | Clinical Trial of Comparative Study of GB221 Pharmacokinetics Metastatic Breast Cancer | Phase 1 | 2011-11-07 |